title: Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience.
abstract: OBJECTIVE
  To prospectively evaluate the feasibility of ferumoxtran-10-enhanced magnetic resonance (MR) imaging at high magnetic field strength (3.0 T) and to compare image quality between 1.5- and 3.0-T MR imaging in terms of lymph node detection in patients with prostate cancer.
  
  
  METHODS
  This study was institutional review board approved, and all patients gave written informed consent. Forty-eight consecutive patients aged 51-79 years (mean, 65.5 years) with prostate cancer were enrolled. T2*-weighted 1.5- and 3.0-T MR images of the pelvis were acquired in a sagittal plane parallel to the psoas muscle 24 hours after ferumoxtran-10 administration. A pelvic and body phased-array coil was used and yielded an in-plane resolution of 0.56 x 0.56 x 3.00 mm at 1.5 T and 0.50 x 0.50 x 2.50 mm at 3.0 T. All images were evaluated by three readers for total image quality, lymph node border delineation, muscle-fat contrast, and vessel-fat contrast. Statistical significance was calculated by using the Mann-Whitney U test. Subsequently, the general linear mixed model was used to estimate the contributions of three factors-patient, reader, and technique-to the variability of the imaging results.
  
  
  RESULTS
  Significantly (P < .05) better muscle-fat contrast, vessel-fat contrast, lymph node border delineation, and total image quality were observed at 3.0-T MR imaging. The general linear mixed model revealed that the variability of all results could be attributed to the use of 3.0-T imaging.
  
  
  CONCLUSIONS
  Ferumoxtran-10-enhanced MR imaging can be performed at high magnetic field strengths and result in improved image quality, which may lead to improved detection of small positive lymph nodes.
authors.affiliation: Department of Radiology and Medical Technology Assessment, University Medical Center Nijmegen, Geert Grooteplein zuid 10, NL 6500 HB, Nijmegen, The Netherlands. r.heesakkers@rad.umcn.nl
authors.forename: Roel A M
authors.initials: RA
authors.lastname: Heesakkers
authors.forename: Jurgen J
authors.initials: JJ
authors.lastname: Fütterer
authors.forename: Anke M
authors.initials: AM
authors.lastname: Hövels
authors.forename: Harrie C M
authors.initials: HC
authors.lastname: van den Bosch
authors.forename: Tom W J
authors.initials: TW
authors.lastname: Scheenen
authors.forename: Yvonne L
authors.initials: YL
authors.lastname: Hoogeveen
authors.forename: Jelle O
authors.initials: JO
authors.lastname: Barentsz
mesh_terms: D000368:Aged; D003287:Contrast Media; D003911:Dextrans; D005240:Feasibility Studies; D052203:Ferrosoferric Oxide; D006801:Humans; D007501:Iron; D008279:Magnetic Resonance Imaging / Q000379:methods; D058185:Magnetite Nanoparticles; D008297:Male; D008875:Middle Aged; D010087:Oxides; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000175:diagnosis*
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide